This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of base of tongue혀 기저부의 악성신생물 (설근부암)

Contents and key points
ItemDetails
A. Classification codesICD-10: C01 | Special Copayment Reduction: V193 (5% copayment for care for the relevant diagnosis for 5 years from the cancer patient registration date)
B. SynonymsBase of tongue cancer, tongue root cancer, oral base cancer; Base of tongue carcinoma, BOT cancer, Tongue base squamous cell carcinoma, Posterior tongue carcinoma
C. Adult onsetLikelihood of first onset in adulthood very high — most are diagnosed in people in their 40s–70s, and HPV-positive cases also occur in relatively young men in their 40s–50s
1. HistorySurgical resection attempts from the 17th century onward, systematization of extensive glossectomy by Billroth and von Langenbeck in the 19th century, combined radiation and chemotherapy in the 20th century, and the introduction of TORS completing modern treatment
2. CausesMultifactorial risk factors including HPV-16 infection (main cause), smoking, alcohol consumption, poor oral hygiene, immunosuppression, and exposure to aromatic hydrocarbons
3. GeneticsHPV+ subtype: E6/E7-mediated inactivation of p53 and Rb, PIK3CA and TRAF3 variants; HPV– subtype: TP53, CDKN2A, FAT1, NOTCH1 somatic mutations, EGFR overexpression
4. General epidemiologyIncreasing incidence of oropharyngeal cancer worldwide, about 3,000 cases of head and neck cancer per year in Korea, male predominance (3:1), concentrated in people in their 40s–70s
5. PathophysiologyMultistep carcinogenesis, abnormal EGFR, PI3K/AKT/mTOR, Wnt, and Notch signaling, immunosuppression in the tumor microenvironment, mechanisms of the HPV E6/E7 oncoproteins
6. SymptomsEarly: foreign body sensation on swallowing, throat discomfort; advanced: dysphagia, otalgia (referred pain), voice disorder, weight loss, neck mass; late: airway obstruction
7. SignsCervical lymphadenopathy (over 70%), tongue fixation, trismus (pterygoid involvement), cranial nerve (IX, X, XII) palsy, mass on endoscopy
8. ScreeningNational cancer screening (visual examination for oral cancer), regular endoscopy for high-risk groups, oral HPV-DNA testing (for research), periodic head and neck examinations for drinkers and smokers
9. DiagnosisCT, MRI, PET-CT, panendoscopy, tissue biopsy, histopathology (mainly squamous cell carcinoma), p16/HPV testing, AJCC 8th edition TNM staging (separate classification by HPV status)
10. TreatmentSurgery (TORS, open resection), IMRT/VMAT radiation (66–70 Gy), concurrent chemoradiotherapy (cisplatin 100 mg/m²), cetuximab, pembrolizumab and nivolumab (recurrent/metastatic), MDT approach
11. Prognosis5-year survival rate over 80% for HPV+ and 40–50% for HPV–; large variation by stage, with early detection, HPV status, and resection margins as key prognostic factors
12. Prevention9-valent HPV vaccine, smoking cessation and moderation of alcohol intake, oral hygiene care, regular oral examinations, early detection programs for high-risk groups
13. ReferencesBray F et al. Global cancer statistics 2022. CA Cancer J Clin. 2024 ... and 9 other papers

1. History

Medical recognition of cancer of the base of the tongue has developed alongside the history of oral cancer as a whole. Ancient Egyptian and Greek physicians recorded ulcerative lesions of the tongue, but a systematic concept of it as a malignant tumor was established only in the modern era. In 17th-century Europe, attempts at surgical resection of intraoral tumors were sporadically reported, and by the late 18th century prototypes of composite resections including the jawbone and tongue began to appear.

The mid-19th century was a landmark period in the history of head and neck surgical oncology. The Austrian surgeon Theodor Billroth and the German von Langenbeck each systematized extensive glossectomy, laying the foundation for surgical treatment of tumors of the floor of the mouth and pharynx, including the base of the tongue. Surgery in this period achieved improved survival thanks to advances in anesthesia, but it was performed without reconstruction and was accompanied by severe functional impairment.

In the early 20th century, Wilhelm Conrad Röntgen's discovery of X-rays (1895) and Marie Curie's research on radioisotopes led to the introduction of radiation therapy. In the 1920s–1940s, radiation alone or combined with surgery was actively tried for oral and pharyngeal cancers, and brachytherapy began to be applied to base of tongue cancer. In the 1960s–1970s, anticancer drugs such as cisplatin were introduced, laying the foundation for concurrent chemoradiotherapy.

From the 1990s onward, as the association between HPV (human papillomavirus) and oropharyngeal cancer was revealed, the epidemiology and pathogenesis of base of tongue cancer were fundamentally redefined. Studies by Gillison et al. in the early 2000s demonstrated that HPV-16 is an independent risk factor for oropharyngeal cancer, which led in 2017 to the establishment in the AJCC 8th edition of separate staging systems for HPV-positive and HPV-negative oropharyngeal cancer.

In the 21st century, transoral robotic surgery (TORS, Transoral Robotic Surgery) and transoral laser microsurgery were introduced, making minimally invasive surgery for base of tongue cancer possible. At the same time, the clinical introduction of IMRT (intensity-modulated radiation therapy) and immuno-oncology agents (pembrolizumab, nivolumab) greatly improved treatment outcomes. In Korea, a multidisciplinary team (MDT) care system for head and neck cancer took full shape after the 2000s, centered on the National Cancer Center, and the Korean Society of Head and Neck Oncology continues to update domestic clinical practice guidelines.


2. Causes

Base of tongue cancer is a multifactorial disease in which multiple risk factors act together rather than a single cause. The major risk factors identified to date are viral infection, smoking, alcohol consumption, immune status, oral hygiene, and occupational exposure.

HPV infection

Human papillomavirus (HPV), especially HPV type 16, has emerged as the most important cause of base of tongue cancer. In the West, 60–80% of oropharyngeal cancers are HPV-related, and this proportion is also increasing in Korea. Oral infection with HPV-16 is reported to increase the risk of oropharyngeal cancer about 15-fold. HPV-positive base of tongue cancer is transmitted mainly through sexual contact, and the risk increases with the number of oral sex partners.

Smoking and alcohol consumption

Carcinogens in tobacco smoke such as polycyclic aromatic hydrocarbons (PAH), nitrosamines, and benzopyrene directly damage the DNA of the oral mucosa. Smoking is the key risk factor for HPV-negative base of tongue cancer, and the risk increases in proportion to the amount smoked (pack-years). Alcohol, especially acetaldehyde, the metabolite of ethanol, causes DNA strand breaks and methylation abnormalities, and combined exposure to smoking and alcohol has a synergistic carcinogenic effect.

Immunosuppression and other factors

Immunosuppressant use after organ transplantation and immunodeficiency due to HIV infection increase the risk of persistent HPV infection and oral cancer severalfold. Poor oral hygiene, chronic mechanical irritation (ill-fitting dental prostheses, etc.), and nutritional deficiencies (lack of vitamins A, C, and E) also act as auxiliary risk factors. Betel nut (areca) chewing is an important risk factor in Southeast Asia but is rare in Korea.


3. Genetics

The molecular genetic understanding of base of tongue cancer centers on the fundamental differences between the HPV-positive (HPV+) and HPV-negative (HPV–) subtypes. The two subtypes differ not only clinically and prognostically but also in their pathogenesis and spectrum of major gene mutations.

Molecular features of the HPV-positive subtype

When HPV integrates into the host cell genome, the viral oncoproteins E6 and E7 are overexpressed. The E6 protein forms a complex with an E3 ubiquitin ligase (E6AP) to degrade and inactivate TP53, and the E7 protein binds the Rb (retinoblastoma) protein, releasing the G1/S cell cycle checkpoint. As a result, p16 (CDKN2A) is reactively overexpressed, and p16 immunohistochemical positivity is used as a surrogate marker of HPV infection. In HPV+ tumors, PIK3CA mutations (25–50%) are common, and TRAF3 deletion and E2F1 amplification are characteristic. FGFR pathway variants are also found.

Molecular features of the HPV-negative subtype

HPV-negative base of tongue cancer is driven by the accumulation of somatic mutations from smoking and alcohol exposure. Mutations in TP53 (60–80%), CDKN2A deletion, and mutations in FAT1 (a cadherin regulating cell adhesion), NOTCH1, and CASP8 are observed at frequencies of 10% or more. EGFR overexpression is prominent, and variants in epigenetic regulatory genes such as KMT2D and NSD1 are also common.

Hereditary syndromes

Fanconi anemia (variants in FANCA, FANCC, etc.) increases the risk of head and neck squamous cell carcinoma dozens of times. Li-Fraumeni syndrome (germline TP53 variants) and BRCA2 variant carriers are also associated with an increased risk of head and neck cancer.

Pharmacogenomics

EGFR overexpression has been studied as a predictor of sensitivity to cetuximab, but expression level alone is difficult to use to predict treatment response. PD-L1 CPS (combined positive score) is used to determine the indication for first-line pembrolizumab treatment, with clinical benefit confirmed at CPS ≥1 or CPS ≥20. TMB (tumor mutational burden) is also being studied as a predictor of response to immuno-oncology agents.


4. General epidemiology

Base of tongue cancer is a major subtype of oropharyngeal cancer and is drawing attention amid a steadily increasing incidence of oropharyngeal cancer worldwide. According to GLOBOCAN data from the International Agency for Research on Cancer (IARC), more than about 100,000 cases of oropharyngeal cancer occur worldwide each year, and HPV-related oropharyngeal cancer shows a steep increase particularly in North America and Northern Europe.

Epidemiology in Korea

According to statistics from the Korea Central Cancer Registry of the National Cancer Center, about 3,000–4,000 new cases of head and neck cancers of the oral cavity and oropharynx occur annually in Korea, and among them, oropharyngeal cancer (tonsil, base of tongue, soft palate, etc.) is increasing. An analysis of head and neck cancer incidence trends in Korea from 1999 to 2012 reported steep increases in the incidence of oral tongue cancer, major salivary gland cancer, tonsil cancer, and hypopharyngeal cancer. In an analysis of oral cancer epidemiology in Korea from 2001 to 2021, the incidence of tongue cancer increased in both men and women, with a particularly notable annual percent change (APC) of 6.13% in women aged 45 or younger.

Sex and age distribution

Base of tongue cancer shows an incidence about 3–4 times higher in men than in women and is concentrated mainly in people in their 40s–70s. HPV-positive base of tongue cancer shows a characteristic epidemiological pattern of increasing among nonsmoking, nondrinking men in their 40s–60s. Geographically, occurrence tends to be concentrated in urban areas, especially the Seoul and Gyeonggi region.

Regional variation

In Southeast Asia and Eastern Europe, where smoking rates are high, HPV-negative oral cancer predominates, whereas HPV-positive oropharyngeal cancer is surging in North America and Northern Europe. Korea has a lower HPV-positive proportion than the West, but the proportion of HPV-positive oropharyngeal cancer is reported to be rising along with recent changes in sexual culture.


5. Pathophysiology

Base of tongue cancer develops through a process of multistep carcinogenesis from normal squamous epithelium to cancer. In this process, inactivation of several tumor suppressor genes and activation of oncogenes occur sequentially or simultaneously.

HPV-mediated carcinogenesis

When HPV-16 infects the basal cells of the oral mucosa or the mucosa of the tonsillar crypts, the viral DNA integrates into the host genome. After integration, the viral oncoproteins E6 and E7 are persistently expressed. E6 degrades the p53 protein, disabling DNA damage surveillance, and E7 binds the Rb protein, releasing the E2F transcription factor and promoting G1→S cell cycle progression. As a result, p16 (CDKN2A) is reactively overexpressed, and p16 immunohistochemistry is used as a surrogate marker of HPV positivity.

Major signaling pathways

EGFR pathway: EGFR is overexpressed in 80–90% of head and neck squamous cell carcinomas, promoting cell proliferation, survival, and invasion through the downstream MAPK/ERK and PI3K/AKT pathways. PI3K/AKT/mTOR pathway: Activated by PIK3CA mutation or amplification or PTEN loss, it promotes protein synthesis and cell growth. Wnt/β-catenin pathway: Increases expression of proliferation-related genes (Cyclin D1, c-Myc) through nuclear accumulation of β-catenin. Notch pathway: A paradoxical role is also observed in which NOTCH1 loss-of-function mutations act as tumor suppressors in head and neck cancer.

Tumor microenvironment (TME)

The TME of base of tongue cancer is rich in immunosuppressive cytokines (TGF-β, IL-10), regulatory T cells (Treg), and myeloid-derived suppressor cells (MDSC), suppressing the antitumor immune response. HPV-positive tumors tend to be richer in CD8+ tumor-infiltrating lymphocytes (TIL) and have higher PD-L1 expression, making them more sensitive to immuno-oncology agents. Tumor angiogenesis (VEGF-mediated) also contributes to local invasion and distant metastasis.


6. Symptoms

Because of its location, base of tongue cancer is difficult to observe directly in the mouth, and its early symptoms are nonspecific, so diagnosis is often delayed. The base of the tongue has few free nerve endings, so pain develops late, and as a result many patients are diagnosed at an advanced stage.

Early symptoms

Early on, a foreign body sensation in the throat, mild discomfort on swallowing, and persistent throat irritation are the main symptoms. Patients often mistake these for simple pharyngitis or reflux esophagitis and neglect them for months. Intermittent sputum or minor bleeding in the mouth may accompany them.

Advanced symptoms

As the tumor grows, dysphagia and odynophagia become prominent, and in severe cases eating solid food becomes impossible. Referred otalgia is referred pain via Jacobson's tympanic nerve of the glossopharyngeal nerve (CN IX); base of tongue cancer should be suspected when a patient complains of ear pain without pain in the trigeminal territory. Hoarseness, which can occur even without vocal cord paralysis, or a hot potato voice may appear.

Late symptoms

When the tumor invades the lateral pharyngeal wall or the masticatory (pterygoid) muscles, trismus develops. With infiltration of the deep tongue muscles, tongue fixation severely impairs articulation and chewing. A neck mass due to cervical lymph node metastasis is reported as the first symptom in more than 30% of cases. With invasion of areas near the airway, dyspnea and airway obstruction may occur, and weight loss and fatigue accompany as systemic symptoms.


7. Signs

Physical examination findings of base of tongue cancer vary by stage, and laryngoscopy or indirect examination of the oropharynx is essential.

Oral and pharyngeal findings

It is difficult to identify a base of tongue tumor by direct oral inspection alone, but abnormal mucosa, ulcers, or masses can be identified by observing the base of the tongue while pressing with a tongue depressor after having the patient protrude the tongue, or with a flexible laryngoscope. The tumor shows an exophytic or endophytic growth pattern, with irregular ulceration and necrotic tissue on the surface.

Cervical lymph nodes

Because the base of the tongue has an abundant lymphatic drainage system, cervical lymph node metastasis is very common. At the initial visit, ipsilateral cervical lymph node metastasis is found in more than 70%, and bilateral metastasis reaches 30%. Metastasis occurs mainly to level II (upper jugular lymph nodes) and level III. On palpation, firm, non-fixed lymph nodes are characteristic, but with extranodal extension (ENE) they adhere to surrounding tissue.

Signs of cranial nerve involvement

When the tumor invades the lateral pharyngeal wall or skull base, cranial nerve palsies develop. With hypoglossal nerve (CN XII) palsy, the tongue deviates toward the paralyzed side, and with vagus nerve (CN X) involvement, abnormal soft palate movement and vocal cord paralysis occur. Pain related to the glossopharyngeal nerve (CN IX) manifests as referred otalgia.

Imaging features

On CT it appears as an irregular, contrast-enhancing mass and is useful for assessing invasion of the deep muscles of the tongue. MRI, with its superior soft-tissue resolution, is excellent for evaluating the extent of tumor involvement, perineural invasion, and skull base invasion. PET-CT is used as standard to evaluate distant metastasis and cervical lymph node status. There is no specific tumor marker on blood tests, but abnormalities in nutritional status markers (albumin, prealbumin) and inflammatory markers (CRP, ESR) may be present.


8. Screening

The Korean National Cancer Screening Program currently does not include a separate screening item for base of tongue cancer (oropharyngeal cancer), but visual examination for oral cancer (oral examination) is performed as part of national cancer screening.

National oral cancer screening

Korea's national cancer screening for oral cancer includes oral examinations for Medical Aid beneficiaries, through which premalignant lesions such as leukoplakia, erythroplakia and ulcerative lesions of the oral mucosa, or early cancers, can be detected. However, the base of tongue is located where it is difficult to examine by direct inspection of the oral cavity, so screening is limited without laryngoscopy or oropharyngeal endoscopy.

Surveillance of high-risk groups

In high-risk groups, such as those with a smoking history of 20 pack-years or more, men with high annual alcohol consumption, and those with a history of multiple sexual partners, periodic head and neck otolaryngology examinations and inspection of the oropharynx by flexible endoscopy are recommended. Regular oral examinations are also needed in immunosuppressed patients (organ transplant recipients, people with HIV infection).

Oral HPV testing

Tests that detect HPV DNA in oral rinse (gargle) samples are being performed for research purposes, but are not currently established as a standard clinical screening test. One study reported that detection of HPV-16 in saliva preceded clinical diagnosis of oropharyngeal cancer by an average of 3.9 years, and its potential as a future screening tool is being examined.

Surveillance of premalignant lesions

Patients with confirmed premalignant lesions such as oral leukoplakia, erythroplakia, or oral lichen planus are recommended to undergo regular follow-up at 3–6 month intervals and biopsy.


9. Diagnosis

Imaging

CT (contrast-enhanced): used as the first-line test to assess cervical lymph node metastasis and bone invasion. It is useful for assessing tumor size and invasion of the lateral pharyngeal wall and masticatory muscles. MRI (T1, T2, contrast-enhanced): with its superior soft-tissue resolution, it precisely evaluates the depth of tongue muscle infiltration, perineural invasion, and skull base invasion. PET-CT: used as a standard test to detect distant metastasis (lung, liver, bone), cervical lymph node metastasis, and heterotopic primary tumors. In particular, in cancer of unknown primary (CUP), where only the cervical lymph nodes are clinically enlarged, the oropharynx including the base of tongue is thoroughly explored.

Endoscopy and biopsy

Panendoscopy includes laryngoscopy, bronchoscopy, and esophagoscopy and is essential for excluding simultaneous primary tumors in patients with head and neck squamous cell carcinoma. Tissue is obtained by endoscopy-guided biopsy or direct biopsy; a sufficient amount of tissue (punch biopsy ≥3 mm) is collected, and p16 immunohistochemistry and HPV PCR/ISH testing are performed together.

Histopathology and molecular testing

About 90% or more of base of tongue cancers are squamous cell carcinoma (SCC); small cell carcinoma, adenocarcinoma, lymphoma, and cancers of minor salivary gland origin also occur rarely. p16 immunohistochemistry is widely used as a surrogate marker for HPV, and strong, diffuse nuclear and cytoplasmic positivity (≥70% of tumor cells) is the criterion for a positive result. Confirmation is by HPV DNA ISH (in situ hybridization) or PCR.

TNM staging (AJCC 8th edition)

The AJCC 8th edition applies separate staging classifications to HPV-positive and HPV-negative oropharyngeal cancer. In HPV-positive oropharyngeal cancer, the nodal metastasis criteria are relaxed so that the same nodal status is classified at a lower stage, reflecting a more favorable prognosis. HPV-negative oropharyngeal cancer follows the traditional head and neck cancer TNM classification. T classification is based on tumor size and invasion of surrounding structures, N classification on lymph node number, size and extranodal extension, and M classification on the presence of distant metastasis.


10. Treatment

Treatment of base of tongue cancer is decided by a multidisciplinary team (MDT), comprehensively considering stage, HPV status, the patient's general condition, and the possibility of functional preservation. The MDT includes head and neck surgery, radiation oncology, internal medicine (hematology-oncology), radiology, pathology, rehabilitation medicine, and a nutrition support team.

Surgery

Transoral robotic surgery (TORS) is a minimally invasive approach using the da Vinci robot that provides oncologic outcomes comparable to open resection in early to intermediate base of tongue cancer while improving functional outcomes. Transoral laser microsurgery (TLM) is also used in combination or as an alternative. During tumor resection, securing resection margins (>5 mm) is key to preventing local recurrence, and neck dissection is performed at the same time. When extensive resection is required, reconstruction is performed using a radial forearm free flap or an anterolateral thigh free flap (ALT flap).

Radiation therapy

IMRT (intensity-modulated radiation therapy)/VMAT is used as the standard radiation technique. A simultaneous integrated boost (SIB) approach is common, prescribing 66–70 Gy (fractionation 2 Gy/fraction) to the primary tumor and metastatic lymph nodes, 60 Gy to high-risk prophylactic regions, and 54–56 Gy to low-risk prophylactic regions. Radiation therapy alone can be an alternative to surgery in early (T1-2N0) base of tongue cancer.

Concurrent chemoradiotherapy

In locally advanced (stage III–IV) base of tongue cancer, concurrent chemoradiotherapy (CRT) is the standard treatment. High-dose cisplatin (100 mg/m², every 3 weeks) is the reference agent for concurrent chemotherapy; when there are concerns about nephrotoxicity or ototoxicity, it is replaced with carboplatin (AUC 1.5–2, once weekly) or cetuximab (400 mg/m² loading followed by 250 mg/m² maintenance, once weekly). Induction chemotherapy (TPF: docetaxel+cisplatin+5-FU) demonstrated a survival benefit in the TAX 324 trial and is used in some indications.

Targeted therapy and immunotherapy

Cetuximab (an EGFR monoclonal antibody) improves survival in locally advanced head and neck cancer when combined with radiation (Bonner trial). In recurrent or metastatic base of tongue cancer, based on the results of the KEYNOTE-048 trial (Phase III), pembrolizumab monotherapy (PD-L1 CPS≥1) or pembrolizumab+cisplatin/carboplatin+5-FU combination therapy has been adopted as first-line standard treatment. Nivolumab demonstrated an overall survival benefit as second-line treatment after failure of platinum-based chemotherapy in the CheckMate 141 trial. In Korea, these immunotherapy agents are also covered by National Health Insurance.


11. Prognosis

The prognosis of base of tongue cancer is determined most strongly by HPV status, TNM stage, resection margins, and extranodal extension (ENE).

Survival by HPV status

HPV-positive base of tongue and oropharyngeal cancers have a 5-year disease-specific survival rate of 80% or more, markedly better than the 40–50% of HPV-negative cancers. HPV-positive patients respond better to treatment even at the same stage, and the success rate of salvage treatment after recurrence is also higher.

Prognosis by stage

StageHPV-positive 5-year survival rateHPV-negative 5-year survival rate
IAbout 90–95%About 60–70%
IIAbout 85–90%About 50–60%
IIIAbout 70–80%About 35–50%
IVAbout 40–60%About 20–35%

Functional outcomes and quality of life

After treatment, swallowing function, voice function, and dry mouth have the greatest impact on quality of life. Radiation side effects have decreased since the adoption of IMRT, but dysphagia and xerostomia remain common long-term complications. After TORS, functional benefits such as a shorter period of nasogastric tube (NGT) dependence and earlier recovery of swallowing function have been reported. Nutritional support (nasogastric or gastrostomy tube) and swallowing rehabilitation should be included from the pre-treatment planning stage.


12. Prevention

Primary prevention

The HPV vaccine is the most powerful means of primary prevention of base of tongue cancer. The current 9-valent HPV vaccine (Gardasil 9) covers HPV types 16, 18, 31, 33, 45, 52 and 58, and the preventive effect is greatest when given before sexual debut (Korean National Immunization Program target: girls aged 12). Vaccination of males also prevents HPV-related oropharyngeal cancer, but it is not yet included in the Korean National Immunization Program (as of 2026).

Smoking cessation is key to preventing HPV-negative base of tongue cancer. Ten years after quitting smoking, the risk of oral cancer decreases significantly. Reducing alcohol: reducing weekly alcohol intake lowers oral cancer risk. Stopping smoking and drinking at the same time doubles the risk-reduction effect.

Secondary prevention

Early detection and appropriate treatment are key to reducing mortality. For men aged 40 or older who smoke and drink, an annual otolaryngology examination, oral inspection, and flexible endoscopy when needed are recommended. When oral premalignant lesions (leukoplakia, erythroplakia) are found, immediate tissue biopsy and follow-up are needed. Oral hygiene care (regular dental checkups, self-observation of the oral mucosa) also contributes to early detection.

Chemoprevention

Retinoids (vitamin A derivatives) have been reported to induce regression of oral premalignant lesions, but their clinical use is limited by toxicity and recurrence. The chemopreventive effect of anti-inflammatory agents such as celecoxib (a COX-2 inhibitor) is at the research stage.


13. References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834

  2. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology. 2015;33(29):3235-3242. DOI: 10.1200/JCO.2015.61.6995

  3. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7

  4. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine. 2016;375(19):1856-1867. DOI: 10.1056/NEJMoa1602252

  5. Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.

  6. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer (TAX 324). New England Journal of Medicine. 2007;357(17):1705-1715. DOI: 10.1056/NEJMoa070956

  7. Chung MK, Im MA, Son YI, et al. Trends in the incidence of and survival rates for oral cavity cancer in the Korean population. Clinical and Experimental Otorhinolaryngology. 2014;7(4):286-292. DOI: 10.3342/ceo.2014.7.4.286

  8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org

  9. Park JO, Joo YH, Jung CK, et al. Trends in Head and Neck Cancer in South Korea Between 1999 and 2012. JAMA Otolaryngology–Head & Neck Surgery. 2016;142(12):1157-1165. DOI: 10.1001/jamaoto.2016.2396

  10. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology. 2010;11(8):781-789. DOI: 10.1016/S1470-2045(10)70017-6